Actively Recruiting
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
Led by University of Michigan Rogel Cancer Center · Updated on 2025-10-20
375
Participants Needed
6
Research Sites
256 weeks
Total Duration
On this page
Sponsors
U
University of Michigan Rogel Cancer Center
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the onset of CLD and determine if PRM can predict the trajectory in lung function decline in affected patients.
CONDITIONS
Official Title
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 3 years or older with no upper age limit
- Received an allogeneic hematopoietic cell transplant
- Signed informed consent by patient or legal guardian; assent if appropriate
- For Cohort 1: Diagnosis of chronic GVHD in at least one organ within the past 3 months using NIH criteria
- For Cohort 2: Diagnosis of chronic lung disease (Bronchiolitis Obliterans Syndrome or Restrictive Lung Disease) within the past 100 days based on specific lung function and imaging criteria
- Patients unable to perform pulmonary function tests may still participate if clinical and radiographic signs support their diagnosis
You will not qualify if you...
- Relapse of primary malignancy or development of secondary hematologic malignancy after transplant
- Having an active, uncontrolled infection
- Requirement of intubation solely to obtain a CT scan for PRM imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Stanford Hospital
Stanford, California, United States, 94305
Actively Recruiting
2
Emory University
Atlanta, Georgia, United States, 30322
Not Yet Recruiting
3
Dana Farber
Boston, Massachusetts, United States, 02215
Not Yet Recruiting
4
The University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
5
MD Anderson
Houston, Texas, United States, 77030
Not Yet Recruiting
6
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
C
Cancer Answerline
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here